Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hyphens Pharma International Days Payable?
Hyphens Pharma InternationalSGX:1J5 -2.70%82 Days Payable is 135.16 as of Jun. 2026, which is 1% below its 10-year median of 135.86. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 119 Medical Distribution companies, Hyphens Pharma International ranks better than 82.35% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Hyphens Pharma International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyphens Pharma International Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hyphens Pharma International's Days Payable distribution charts can be found below:
* The bar in red indicates where Hyphens Pharma International's Days Payable falls into.
Hyphens Pharma International Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International (SGX:1J5) has a Days Payable of 135.16 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyphens Pharma International and its competitors. This is near median its historical median of 135.86. Over the past decade, Hyphens Pharma International's Days Payable has ranged from 120.95 to 150.18. According to the industry distribution chart, Hyphens Pharma International ranks #21 out of 119 companies in the Medical Distribution industry, placing it in the top 17.6%.
Is Hyphens Pharma International's Days Payable too high?
Hyphens Pharma International's current Days Payable of 135.16 is near median its 10-year median of 135.86. Over the past 10 years, this metric has ranged from a low of 120.95 to a high of 150.18. The Medical Distribution industry median Days Payable is 78.20. Hyphens Pharma International's value of 135.16 is 72.8% above this industry median. Based on the distribution chart, Hyphens Pharma International ranks #21 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hyphens Pharma International ranks #21 out of 119 companies for Days Payable. This places Hyphens Pharma International in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 78.20. Hyphens Pharma International's value of 135.16 is 72.8% above this benchmark. Historically, Hyphens Pharma International's own Days Payable has ranged from 120.95 to 150.18 over the past decade. While the company's 10-year median is 135.86 vs. the industry median of 78.20, Hyphens Pharma International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 78.20, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current Days Payable of 135.16 is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyphens Pharma International and its competitors. For the Medical Distribution industry, the median Days Payable is 78.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current Days Payable is 135.16, which is near median its own 10-year median of 135.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current Days Payable is 135.16, which is near median its 10-year median of 135.86 and 72.8% above the Medical Distribution industry median of 78.20. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current Days Payable is 135.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
Days Payable: 135.16 (near median its 10-year median of 135.86)
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
Industry Position: 72.8% above the Medical Distribution median (#21 of 119)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
